Associate professor

Mark Oremus.

Contact information

Office: LHN 3731

Phone: 519-888-4567, ext. 35129


Research interests

My primary research interests include aging and chronic disease, cognition, dementia, and Alzheimer’s disease.  I have conducted studies on willingness-to-pay for Alzheimer’s disease medications, measuring quality-of-life in Alzheimer’s disease, and the use of outcome measurement instruments in Alzheimer’s disease drug trials.  My other research interests include systematic reviews, population and public health from a life-course perspective, health policy and economics, and knowledge transfer.

Graduate supervision and student opportunities

I am currently accepting applications from graduate students with related research interests:

  • Aging
  • Epidemiology

Graduate studies application details

Teaching interests

  • Epidemiology
  • Population and public health 
  • Mixed methods


BA, Political Science (McGill University)

MA, Public Policy and Administration (Concordia University)

MSc, Epidemiology and Biostatistics (McGill University)

PhD, Epidemiology and Biostatistics (McGill University)

Selected publications

See Google Scholar for full list of publications.

Hosseini S, Oremus M. The effect of age of initiation of cannabis use on psychosis, depression, and anxiety among youth under 25 years. Can J Psychiatry. 2018. doi: 10.1177/0706743718809339. [Epub ahead of print]

Miller S, Wu RKS, Oremus M. The association between antibiotic use in infancy and childhood overweight or obesity: a systematic review and meta-analysis. Obes Rev. 2018;19(11):1463-1475.

Sharma S, Oremus M. PRISMA and AMSTAR show systematic reviews on health literacy and cancer screening are of good quality. J Clin Epidemiol. 2018;99:123-131.

Oremus M, Sharafoddini A, Morgano GP, Jin X, Xie F. A computer-assisted personal interview app in research electronic data capture for administering time trade-off surveys (REDCap): development and pretest. JMIR Formative Res. 2018;2:e3.

Majoni M, Oremus M. Does being a retired or employed caregiver affect the association between behaviours in Alzheimer’s disease and caregivers’ health-related quality-of-life? BMC Res Notes. 2017;10:766.

Oremus M, Xie F, Pullenayegum E, Gaebel K. Can the general public use vignettes to discriminate between Alzheimer’s disease health states? BMC Geriatr. 2016;16:36.

Randhawa H, Jiwa A, Oremus M. Identifying the components of clinical vignettes describing Alzheimer's disease or other dementias: a scoping review. BMC Med Inform Decis Mak. 2015;15:54.

Oremus C, Oremus M, McNeely H, Losier B, Parlar M, King M, et al. Effects of electroconvulsive therapy on cognitive functioning in patients with depression: protocol for a systematic review and meta-analysis. BMJ Open. 2015;5(3):e006966.

Banerjee AT, Strachan PH, Boyle MH, Anand SS, Oremus M. Factors facilitating the implementation of church-based heart health promotion programs for older adults: a qualitative study guided by the precede-proceed model. Am J Health Promot. 2015;29(6):365-373.

Soskolne CL, Al-Delaimy WK, Burns K, Finch MR, Gaudino Jr JA, Lanphear B, Oremus M, Phillips L, Ruff K, Weiss SH, Wing S. Competing interests in epidemiology [letter]. BMJ. 2015;350:g7744.

Oremus M. Does the evidence say a 4-point change in ADAS-cog score is clinically significant? Alzheimers Dement. 2014;10(3):416-417.

Oremus M, Tarride JE, Clayton N, Canadian Willingness-to-Pay Study Group, Raina P. Health utility scores in Alzheimer's disease: differences based on calculation with American and Canadian preference weights. Value Health. 2014;17(1):77-83.

Oremus M, Postuma R, Griffith L, Balion C, Wolfson C, Kirkland S, Patterson C, Shannon HS, CLSA Algorithms Validation Group, Raina P. Validating chronic disease ascertainment algorithms for use in the Canadian Longitudinal Study on Aging. Can J Aging. 2013;32(3):232-239.

Oremus M, Tarride JE, Pullenayegum E, Clayton N, Canadian Willingness-to-pay Study Group, Raina P. Patients’ willingness-to-pay for an Alzheimer’s disease medication in Canada. The Patient. 2013;6(3):161-168.

Oremus M, Tarride JE. Modeling cost-effectiveness of pharmaceuticals in Alzheimer’s disease. Expert Rev Pharmacoecon Outcomes Res. 2012;12(3):275-277.

Oremus M, Oremus C, Hall GB, McKinnon MC, ECT & Cognition Systematic Review Team. Inter-rater and test-retest reliability of quality assessments by novice student raters using the Jadad and Newcastle-Ottawa Scales. BMJ Open. 2012;2(4): e001368.

Oremus M, Santaguida P, Walker K, Wishart LR, Siegel KL, Raina P. Studies of stroke rehabilitation therapies should report blinding and rationalize use of outcome measurement instruments. J Clin Epidemiol. 2012;65(4):368-374.

Oremus M, Dayes I, Walker K, Raina P. Systematic review: conservative treatments for secondary lymphedema. BMC Cancer. 2012;12(1):6.

Xie F, Oremus M, Gaebel K. Measuring health-related quality-of-life for Alzheimer’s disease using the general public. Qual Life Res. 2012;21(4):593-601.

Oremus M, Aguilar SC. A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada. Pharmacoeconomics. 2011;29(2):141-156.

Oremus M, Raina P, Eva K, Lavis JN, Nair K, Lo A, Smith S. Impact of clinician judgment on formulary committees' recommendations in Canada. J Health Serv Res Policy. 2010;15(2):98-105.

University of Waterloo